“Nursing is at the forefront of symptom management, and nurse-designed interventions lead the way,” Gwen Wyatt, RN, PhD, FAAN, FAPOS, recipient of the 2020 ONS Distinguished Nurse Researcher Award, said in a session at the inaugural ONS Bridge^TM virtual conference in September 2020. She shared lessons from her career journey and told nurses that ONS can help them get their ideas “off the drawing board.”

First-line therapy combining nivolumab with chemotherapy improved median overall survival rates in patients with PD-L1-expressing gastric cancer by 3.3 months in a large international, multicenter trial. The findings were reported during the 2020 European Society for Medical Oncology virtual meeting.

Turning on the body’s inflammasome with epigenetic therapy may improve the efficacy of PARP inhibitors across multiple tumor types, possibly expanding the therapy’s application to new cancers, researchers reported in Proceedings of the National Academy of Sciences.

Our 2009–2014 study, Bridging Geographic Barriers: Remote Cancer Genetics Counseling for Rural Women, also known as the REACH Project (Risk Education and Assessment for Cancer Heredity), was the first randomized, noninferiority trial of telephone-based BRCA1 and BRCA2 counseling and testing that used a population-based traceback approach to identify and counsel both rural and urban women who were at increased risk for hereditary breast and ovarian cancer but had not received genetic counseling or testing.

When genetically modified with a chimeric antigen receptor (CAR), natural killer T (NKT) cells eliminated 50% of metastases in a patient with heavily pretreated, relapsed or refractory metastatic neuroblastoma, according to interim findings from an ongoing study that were published in Nature Medicine.

The COVID-19 coronavirus continues to smother the United States, and nationwide efforts to flatten the curve aren’t lowering cases or preventing deaths. U.S. Food and Drug Administration (FDA) Commissioner Stephen M. Hahn, MD, an oncologist by training and profession, addressed the actions needed to combat COVID-19. One in particular is ensuring that clinical trials accurately reflect diverse populations.

October 31, 2020, marked an important milestone in American public health: the 80th anniversary of President Franklin Delano Roosevelt’s dedication of the campus of the National Institutes of Health (NIH) in Bethesda, MD. 

Many older adults are continuing cancer screenings beyond the recommended upper age limits, which range from age 65–75 years depending on the type of cancer screening, researchers reported in JAMA Network Open.

Healthy older adults who take daily low-dose aspirin have increased risk of being diagnosed with advanced cancers and dying from cancer, according to findings from a new study published in the Journal of the National Cancer Institute.

Forty-eight percent of women with gynecologic cancers report experiencing clinically significant fatigue after surgery that may continue six months (44%) and one (39%) year later, researchers reported in study findings published in Cancer.

Telehealth resources have been present in the United States for several decades. Traditionally, clinicians used telehealth to help rural populations with limited access to care. However, telehealth innovations expand beyond home care coordination. We can use technology to reach even the most remote and vulnerable patients.  

Oral anticancer agents are often expensive, and ensuring that patients have the financial means to pay for the medication is the first important step to improving adherence rates. Each health system has a group of individuals, not technology, to manage access to financial assistance. Even if they can afford the therapy, however, patients often struggle to maintain oral adherence.

Science, our reliance on the foundations of epidemiology, and management of a public health crisis have been unprecedented discussion topics this year. We have never had a greater need to rely on data, science, and the evolving understanding of experts about the COVID-19 coronavirus and how to contend with it.

Until recently, past ONS President Deborah Mayer, PhD, RN, AOCN^®, FAAN, served as interim director of the National Cancer Institute’s (NCI’s) Office of Cancer Survivorship, a part of the Division of Cancer Control and Population Sciences. As an oncology nurse, Mayer brought a special perspective to the office’s mission to better understand and meet the unique needs of the growing number of U.S. cancer survivors.

Patients throughout the United States still face persistent inequities across the healthcare continuum because of social determinants of health and inequity in research, Shannon N. Zenk, PhD, MPH, RN, FAAN, director of the National Institute of Nursing Research (NINR) recognized.

Cervical cancer rates have dropped more than 90% among women who received the human papillomavirus (HPV) vaccine, according to the results of a Swedish study published in the New England Journal of Medicine. Global health leaders are calling it a milestone study. 

On October 2, 2020, the U.S. Food and Drug Administration (FDA) approved nivolumab in combination with ipilimumab for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery. This is the first drug regimen approved for mesothelioma in 16 years and the second FDA-approved systemic therapy for mesothelioma. 

Thanks to expanded Medicaid coverage from the Affordable Care Act (ACA), women diagnosed with breast cancer—and in particular, African American women who are more likely to experience breast cancer disparities—are getting their cancers found at earlier stages, according to researchers. The study findings were reported in JAMA Surgery.

Although opioid-related deaths are increasing in the general U.S. population, leading to the U.S. Department of Health and Human Services declaring it a public health emergency, new research shows that the increase is much smaller among patients with cancer, even though opioids are used as an option for cancer-related pain. The findings were published in JAMA Oncology.

The disproportionate adverse health impact from smoking on African Americans is striking. Although oncology nurses are well aware of tobacco’s carcinogenic effects, they also need to understand the implications for comorbid conditions they may see in smokers with cancer. A recent study, through the National Institutes of Health (NIH), confirmed that African Americans have a 2.5 times higher incident of smoking-related strokes than those who never smoke.

A new drug is extending both remission and survival in adults with acute myeloid leukemia (AML), according to findings reported at the American Society of Hematology annual meeting in December 2019. The study was funded by Celgene, the drug’s manufacturer.

Combination immunotherapy treatments are revolutionizing the way cancer care is delivered. As an ongoing evolution of care, nurses are administering different treatment modalities on a regular basis. Treatments include using multiple immunotherapy drugs in tandem, combining chemotherapy with immunotherapy, using targeted therapies with immunotherapy, and even involving radiation with immunotherapy. The move toward multiple-drug modalities will continue to change nursing practice, and nurses must have a basis of knowledge and evidence from which to work.

While the world is in the throes of the COVID-19 coronavirus pandemic, cancer research marshals forward with a focus on CAR T-cell therapy. 

From international guidelines to economic stimulus and legislative support, the COVID-19 coronavirus pandemic is now global leaders’ top priority. Leading the research efforts is the National Institutes for Health’s (NIH) National Institute of Allergy and Infectious Disease (NIAID). As NIAID’s director for more than 30 years, Anthony Fauci, MD is one of the few, regular faces associated with COVID-19 in the United States. On April 23, 2020, the agency announced that it will spearhead a strategic plan to research a vaccine for COVID-19. 

As the world embarks on unprecedented research efforts to prevent and treat the COVID-19 coronavirus, patients with cancer and healthcare providers alike may be interested in using herbal products to boost their immune system or relieve anxiety and stress. However, finding accurate information is challenging: no herbs have been scientifically proven to prevent or treat COVID-19, and some may even cause harm.

Most of the global biomedical research community, especially those at the National Institutes of Health (NIH), is consumed with the COVID-19 coronavirus pandemic. Because the U.S. federal government is under strict orders to limit its operations to only essential personnel, many of the 27 NIH institutes and centers are redirecting their efforts toward COVID-19 topics. However, the National Cancer Institute (NCI) is continuing its cancer research in certain priority areas.   

Sleep disturbances such as insomnia are prevalent and persistent among cancer survivors and diminish quality of life. Because of adverse effects such as continued sleep difficulty, memory disturbances, and falls associated with conventional medications, many patients prefer nonpharmaceutical options to address their insomnia.

Combining a traditional 12-point biopsy with magnetic resonance imaging (MRI) improves the accuracy of prostate cancer diagnosis, according to findings from a new National Institutes of Health (NIH) study published in the New England Journal of Medicine. 

Children with acute lymphoblastic leukemia (ALL) at risk for cancer recurrence in the brain don’t need prophylactic radiation therapy, researchers reported in the Journal of Clinical Oncology. 

Overall cancer death rates fell 1.5% on average per year from 2001–2017 in the United States for all cancer sites combined, according to the Annual Report to the Nation on the Status of Cancer from the Centers for Disease Control and Prevention (CDC), National Cancer Institute (NCI), American Cancer Society, and North American Association of Central Cancer Registries.

Medical cannabis has been approved for use in more than 33 states, many of which have decriminalized its use as well, and a health policy wave has spread across the country through state referendums to ease the burden for legalizing cannabis for health purposes. It’s a different world than it was 30 years ago, and the National Institute on Drug Abuse (NIDA) is frequently called to testify before Congress to address concerns and questions from lawmakers.

Patient-centered research is vital in the effort to move the needle in cancer care, and nurse researchers rely on funding from organizations like the Patient-Centered Outcomes Research Institute (PCORI) to support new and ongoing studies. In December 2019, the U.S. House of Representatives approved the Further Consolidation Appropriations Act, 2020 (H.R. 1865), extending funding for PCORI through fiscal year 2029.

A new type of dual-function oncolytic virus that simultaneously kills cancer cells while increasing levels of leptin to support T cells is showing promise in melanoma mouse models, researchers reported in Immunity.   

As use of ambulatory care settings continues to grow, so too does the demand for expertly trained nurses to staff them. Unfortunately, nurse staffing levels have struggled to meet the burgeoning need in ambulatory clinics throughout the country. Traditionally, undergraduates receive limited ambulatory-specific education in nursing school, leaving them unprepared to enter those settings after graduation. However, the nursing shortage complicates staffing issues, and we must develop programs to direct new graduate nurses into ambulatory oncology careers.  

Although U.S. smoking rates have hit an all-time low of 14%, 34 million American adults are still considered active smokers, according to the U.S. surgeon general’s January 2020 report on smoking cessation. It’s the first new report focused directly on smoking cessation from the surgeon general’s office in 30 years. 

Overall U.S. cancer mortality fell 2.2% from 2016 to 2017, the largest reduction for a single year, according to the American Cancer Society’s “Cancer Statistics, 2020,” published in CA: A Cancer Journal for Clinicians.

As more people receive the human papillomavirus (HPV) vaccine to protect themselves from strains of the virus that can cause cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers, researchers are starting to see herd immunity, where even people who haven’t received the vaccine are developing fewer oral HPV infections. The findings were published in JAMA.

Modest differences may exist among women with diabetes compared to healthy controls when it comes to adhering to screening recommendations for breast, cervical, and colorectal cancers, according to results of a study published in Diabetologia.

Participation in clinician and patient conversations about lung cancer screening—as well as the actual screening itself—is relatively low. According to one study, only 3.9% of screening-
eligible patients had undergone lung cancer screening. Because the screening recommendations are newer, most patients are unaware that they exist, and research highlights that only 10%–12% of the patient population has had conversations with their clinicians about it.

Identifying a panel of tumor-associated antigens and autoantibodies through a simple blood test may one day help providers diagnose the earliest stages of breast cancer, before clinical signs appear.

Pegilodecakin, an investigational, first-in-class drug currently in clinical trials, is demonstrating positive safety results and measurable responses when used in combination with pembrolizumab or nivolumab in patients with non-small cell lung cancer (NSCLC) or kidney cancer. The findings from the multicenter, phase IB study were published in Lancet Oncology.

On January 23, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

To better understand the demands and demographics of the larger RN community, the Health Resources Services Agency (HRSA) compiled data from the National Sample Survey of RNs (NSSRN). Released in January 2020, the report is a compendium of information and questions RNs have answered about different aspects of the life and work. The data collected since 1977 provides insight into the latest trends and future workforce projections, and HRSA uses it to help allocate workforce resources.

The push and pull of budget negotiations makes for great headlines, but more important is the outcome when lawmakers finally arrive at a consensus. Earlier in December, the National Institutes of Health announced a $2.6 billion overall increase in funding, including a $297 million increase to the National Cancer Institutes (NCI), for fiscal year 2020.

Men have higher death rates than women across all stages of breast cancer, study findings reported in JAMA Oncology show. In the study, five-year overall survival after a breast cancer diagnosis was 77.6% for men and 86.4% for women.

Kratom is a Southeast Asian tropical tree, the leaves of which have been chewed, smoked, or made as tea for their stimulant and euphoric effects. They have also been employed in traditional medicine to reduce pain and fever, to relieve diarrhea, for wound healing, and as a substitute for opium. Recently, kratom supplements have become popular in the United States for alleviating pain, improving mood, lowering anxiety, and alternative opioid withdrawal treatment.

After nine months of follow-up, 44% of patients in a comprehensive tobacco treatment program were compliant with smoking abstinence, according to the results of a study published in JAMA Network Open.

Systemic use of exercise prescriptions not only lowers the risk of certain cancers but also helps to improve side effects and survival from cancer and should therefore be incorporated into cancer treatment plans, experts from the American College of Sports Medicine and 17 partner organizations said in articles published in Medicine and Science in Sports and Exercise and CA: A Cancer Journal for Clinicians.

According to findings from a new analysis published in JAMA Oncology, multigene testing should be expanded to all women with breast cancer and not just those with certain family histories or clinical factors.

Bioengineers may have found a way to use tamoxifen activated with blue light to control precisely which tissues and body areas CAR T cells attack, reducing toxicities in other parts of the body. They reported their work in ACS Synthetic Biology.